SUVEN PHARMACEUTICALS Financial Statement Analysis
|
||
The Revenues of SUVEN PHARMACEUTICALS have increased by 30.75% YoY .
The Earnings Per Share (EPS) of SUVEN PHARMACEUTICALS has decreased by -9.37 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
SUVEN PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 543064|NSE : SUVENPHAR]
Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
---|---|---|---|---|---|
Revenues | ₹1,320 Cr | ₹1,010 Cr | ₹834 Cr | ₹378 Cr | ₹378 Cr |
Expenses | ₹739 Cr | ₹567 Cr | ₹449 Cr | ₹206 Cr | ₹206 Cr |
Operating Profit (Excl OI) | ₹582 Cr | ₹443 Cr | ₹385 Cr | ₹172 Cr | ₹172 Cr |
Other Income | ₹92 Cr | ₹14 Cr | ₹18 Cr | ₹0.60 Cr | ₹0.60 Cr |
Interest | ₹8.53 Cr | ₹12 Cr | ₹23 Cr | ₹2.79 Cr | ₹2.79 Cr |
Depreciation | ₹39 Cr | ₹32 Cr | ₹24 Cr | ₹11 Cr | ₹11 Cr |
Profit Before Tax | ₹668 Cr | ₹414 Cr | ₹356 Cr | ₹158 Cr | ₹158 Cr |
Profit After Tax | ₹454 Cr | ₹309 Cr | ₹269 Cr | ₹109 Cr | ₹109 Cr |
Consolidated Net Profit | ₹454 Cr | ₹362 Cr | ₹317 Cr | ₹109 Cr | ₹109 Cr |
Earnings Per Share (Rs) | ₹16.16 | ₹17.83 | ₹14.23 | ₹24.91 | ₹0.00 |
PAT Margin (%) | 30.66 | 34.35 | 30.56 | 32.24 | 28.92 |
ROE(%) | 25.21 | 33.52 | 30.47 | 37.80 | 18.92 |
ROCE(%) | 33.41 | 45.92 | 36.19 | 44.55 | 23.87 |
Total Debt/Equity(x) | 0.04 | 0.06 | 0.12 | 0.22 | 0.14 |
Key Financials |
||
Market Cap | : | ₹ 17,226.2 Cr |
Revenue (TTM) | : | ₹ 1,167.8 Cr |
Net Profit(TTM) | : | ₹ 370.9 Cr |
EPS (TTM) | : | ₹ 14.6 |
P/E (TTM) | : | 46.4 |
Industry Peers & Returns | 1W | 1M | 1Y |
SUVEN PHARMACEUTICALS | 5.1% | -3.2% | 38.4% |
SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
CIPLA | 2.5% | 0.4% | 71.7% |
DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
MANKIND PHARMA | NA | NA | NA |
TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
LUPIN | 2.8% | 0% | 147.8% |
SUVEN PHARMACEUTICALS Revenues
[BOM: 543064|NSE : SUVENPHAR]
Y-o-Y | 30.75 % |
5 Yr CAGR | 36.72 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2023 | ₹1,320 Cr | 30.75 | |
Mar2022 | ₹1,010 Cr | 21.10 | |
Mar2021 | ₹834 Cr | 120.68 | |
Mar2020 | ₹378 Cr | 0.00 | |
Mar2019 | ₹378 Cr | - |
SUVEN PHARMACEUTICALS Operating Profit
[BOM: 543064|NSE : SUVENPHAR]
Y-o-Y | 31.31 % |
5 Yr CAGR | 35.70 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2023 | ₹582 Cr | 31.31 | |
Mar2022 | ₹443 Cr | 15.14 | |
Mar2021 | ₹385 Cr | 124.28 | |
Mar2020 | ₹172 Cr | 0.00 | |
Mar2019 | ₹172 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | 0.43 % |
5 Yr CAGR | -0.75 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2023 | 44.06% | 0.43 | |
Mar2022 | 43.87% | -4.94 | |
Mar2021 | 46.15% | 1.65 | |
Mar2020 | 45.4% | 0.00 | |
Mar2019 | 45.4% | - |
SUVEN PHARMACEUTICALS Profit After Tax
[BOM: 543064|NSE : SUVENPHAR]
Y-o-Y | 25.24 % |
5 Yr CAGR | 42.75 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2023 | ₹454 Cr | 25.24 | |
Mar2022 | ₹362 Cr | 14.30 | |
Mar2021 | ₹317 Cr | 190.10 | |
Mar2020 | ₹109 Cr | 0.00 | |
Mar2019 | ₹109 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | -10.74 % |
5 Yr CAGR | 1.47 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2023 | 30.66 % | -10.74 | |
Mar2022 | 34.35 % | 12.40 | |
Mar2021 | 30.56 % | -5.21 | |
Mar2020 | 32.24 % | 11.48 | |
Mar2019 | 28.92 % | - |
SUVEN PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 543064|NSE : SUVENPHAR]
Y-o-Y | -9.37 % |
5 Yr CAGR | 0 |
Years | EPS | % Change | |
---|---|---|---|
Mar2023 | ₹16 | -9.37 | |
Mar2022 | ₹18 | 25.30 | |
Mar2021 | ₹14 | -42.87 | |
Mar2020 | ₹25 | 0 | |
Mar2019 | ₹0.00 | - |
SUVEN PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 543064|NSE : SUVENPHAR]
Y-o-Y | -27.24 % |
5 Yr CAGR | 8.77 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2023 | 33.41% | -27.24 | |
Mar2022 | 45.92% | 26.89 | |
Mar2021 | 36.19% | -18.77 | |
Mar2020 | 44.55% | 86.64 | |
Mar2019 | 23.87% | - |
SUVEN PHARMACEUTICALS Share Price vs Sensex
Current Share Price | : | ₹676.6 |
Current MarketCap | : | ₹ 17,226.2 Cr |
Updated EOD on | : | Mar 28,2024 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
SUVEN PHARMACEUTICALS | 5.1% |
-3.2% |
38.4% |
SENSEX | -0.4% |
-0.9% |
25.8% |
SUVEN PHARMACEUTICALS related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE 400 MIDSMALLCAP | 2.1% | -3.5% | 55.9% |
S&P BSE 250 SMALLCAP | 2% | -5.8% | 56.3% |
S&P BSE MIDSMALLCAP | 1.9% | -4.4% | 61.2% |
S&P BSE SMALL CAP | 1.8% | -6.7% | 58.8% |
S&P BSE HEALTHCARE | 1% | -3.2% | 60.6% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY MID SMALL400 | 2.4% | -3.7% | 58.5% |
NIFTY SMALLCAP250 | 2.1% | -6.1% | 61.4% |
NIFTY500 MULTICAP 50:25:25 | 1.3% | -2.4% | 46.5% |
NIFTY 500 | 0.8% | -1.4% | 39.7% |
You may also like the below Video Courses
FAQ about SUVEN PHARMACEUTICALS Financials
How the annual revenues of SUVEN PHARMACEUTICALS have changed ?
The Revenues of SUVEN PHARMACEUTICALS have increased by 30.75% YoY .
How the Earnings per Share (EPS) of SUVEN PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of SUVEN PHARMACEUTICALS has decreased by -9.37 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs